Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of three doses of topical
NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center
of the scalp (Norwood/Hamilton grades III-IV androgenetic alopecia). Four equally sized
treatment groups (35 men each) will receive either NEOSH101 0.5%, NEOSH101 1.0%, NEOSH101
2.0% or placebo. A 12-week observation period will follow the treatment period.